Clinical Trials Browser

Phase 1/2 × Recurrence × fludarabine × Clear all

NCT05826535 2026-04-15

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT02625480 2026-04-09

ZUMA-4

Phase 1/2 Completed

Recurrence, Lymphoma, B-Cell

NCT03793478 2026-04-01

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1/2 Active not recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT07502287 2026-03-30

DUAL-NK-NB

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

NCT04416984 2026-03-04

ALPHA2

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06096038 2026-02-20

Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

Phase 1/2 Recruiting

Head and Neck Neoplasms, Neoplasms, Recurrence

NCT03573700 2025-11-18

Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

24 enrolled 9 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Lymphoid, Recurrence, Leukemia, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence

NCT06838832 2025-07-30

Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHL

Phase 1/2 Recruiting

Recurrence

NCT06834529 2025-02-19

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

NCT02614066 2024-11-19

ZUMA-3

Phase 1/2 Completed

125 enrolled 27 charts 2 FDA

Recurrence

NCT03658785 2024-08-13

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1/2 Recruiting

Neoplasm Metastasis, Recurrence

NCT03056339 2024-03-25

Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies

Phase 1/2 Completed

49 enrolled 12 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04030195 2023-01-31

Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL

Phase 1/2 Completed

18 enrolled 13 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT01289457 2020-02-24

Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome

Phase 1/2 Completed

282 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT03916679 2019-04-16

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

Phase 1/2 Unknown

Ovarian Neoplasms, Recurrence

NCT01322776 2011-03-25

Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

Phase 1/2 Unknown

Recurrence, Lymphoma, Mantle-Cell